

HEPATITIS B IN THE UNITED STATES

First generation Asian communities: Why test now?



IF LEFT UNTREATED, up to **1 in 4 people** with chronic hepatitis B (CHB) develop liver problems such as cirrhosis and liver cancer¹

15%-40%

APPROXIMATELY **15% to 40%** of persons with CHB develop cirrhosis, HCC, or liver failure, which leads to substantial morbidity and mortality²


100x

PERSONS WITH CHB:
• are **100x more likely** to develop liver cancer than uninfected persons³
– A 5-year cumulative risk of developing liver cancer in patients with cirrhosis is 5% to 30%³

22 YEARS

• die an average of **22 years earlier** than uninfected persons⁴

Although Asian and Pacific Islanders make up about 6% of the US population, they currently account for **more than 58% of Americans with CHB**⁵



APPROXIMATELY **1 IN 12** ASIAN AMERICANS HAVE CHB⁷

CHB-ASSOCIATED LIVER CANCER IS ONE OF THE **MOST SERIOUS HEALTH DISPARITIES** IN ASIAN AMERICANS⁷

>80% UNDIAGNOSED

More than 80% of persons **in the United States** with CHB are undiagnosed⁸

3 TESTS TO ORDER

A simple blood test, which is covered by most insurance, will look for^{9,10}:

- HBsAg** (hepatitis B surface antigen)
- anti-HBs** (hepatitis B surface antibody)
- anti-HBc** (hepatitis B core antibody)

To ensure reimbursement eligibility, confirm with patient's insurance coverage.

Test for hepatitis B

References: **1.** Centers for Disease Control and Prevention. Hepatitis B questions and answers. CDC website. Updated April 7, 2021. Accessed June 13, 2022. <https://www.cdc.gov/knowhepatitisb/faqs.htm> **2.** US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2020;324(23):2415-2422. **3.** National Cancer Institute. National Institutes of Health, US Department of Health and Human Services. Liver (Hepatocellular) Cancer Prevention (PDQ[®])—Health Professional Version. NCI website. Updated March 2, 2022. Accessed June 13, 2022. https://www.cancer.gov/types/liver/hp/liver-prevention-pdq#_177_toc **4.** Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. *Clin Infect Dis*. 2014;58(1):40-49. **5.** Centers for Disease Control and Prevention. Viral hepatitis populations: Asian & Pacific Islanders. CDC website. Updated September 24, 2020. Accessed June 13, 2022. https://www.cdc.gov/hepatitis/populations/Born-Outside-United-States.htm?CDC_AA_reVal=https%3A%2F%2Fwww.cdc.gov%2Fhepatitis%2Fpopulations%2Fapi.htm **6.** Gish RG, Cohen CA, Block JM, et al. Data supporting updated estimates of the prevalence of chronic hepatitis B and C in the United States. *Hepatology*. 2015;62:1339-1341. **7.** Centers for Disease Control and Prevention. Asian American & Pacific Islander Heritage. CDC website. Published March 3, 2020. Accessed June 13, 2022. <https://www.cdc.gov/healthequity/features/asian-pacific/index.html> **8.** Ogawa E, Yeo YH, Dang N, et al. Diagnosis rates of chronic hepatitis B in privately insured patients in the United States. *JAMA Netw Open*. 2020;3(4):e201844. doi:10.1001/jamanetworkopen.2020.1844 **9.** Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. *Hepatology*. 2009;49(suppl 5):S35-S44. **10.** Centers for Disease Control and Prevention. Viral hepatitis preventive services. CDC website. Updated May 5, 2020. Accessed June 13, 2022. https://www.cdc.gov/nchstp/highqualitycare/preventiveservices/hepatitis.html?CDC_AA_reVal=https%3A%2F%2Fwww.cdc.gov%2Fncchstp%2Fpreventionthroughthehealthcare%2Fpreventiveservices%2Fhepatitis.htm



HEPBMD, the HEPBMD Logo, the Liver Icon, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc. ©2022 Gilead Sciences, Inc. All rights reserved. US-UNBP-1061 07/22

hepBMD™

Persons depicted are models used for illustrative purposes and are not actual patients.

